A detailed history of Geode Capital Management, LLC transactions in Reneo Pharmaceuticals, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 214,499 shares of RPHM stock, worth $360,358. This represents 0.0% of its overall portfolio holdings.

Number of Shares
214,499
Previous 201,036 6.7%
Holding current value
$360,358
Previous $303,000 20.13%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$1.34 - $1.7 $18,040 - $22,887
13,463 Added 6.7%
214,499 $364,000
Q2 2024

Aug 09, 2024

SELL
$1.51 - $1.9 $198,817 - $250,167
-131,667 Reduced 39.57%
201,036 $303,000
Q1 2024

May 13, 2024

SELL
$1.59 - $1.74 $10,872 - $11,898
-6,838 Reduced 2.01%
332,703 $552,000
Q4 2023

Feb 13, 2024

BUY
$1.34 - $8.43 $11,942 - $75,128
8,912 Added 2.7%
339,541 $543,000
Q3 2023

Nov 13, 2023

BUY
$5.44 - $8.13 $196,759 - $294,053
36,169 Added 12.28%
330,629 $2.52 Million
Q2 2023

Aug 11, 2023

BUY
$5.44 - $10.5 $1.08 Million - $2.08 Million
197,849 Added 204.79%
294,460 $1.93 Million
Q1 2023

May 15, 2023

BUY
$2.44 - $6.42 $20,244 - $53,266
8,297 Added 9.39%
96,611 $577,000
Q4 2022

Feb 13, 2023

SELL
$1.8 - $3.52 $340 - $665
-189 Reduced 0.21%
88,314 $205,000
Q3 2022

Nov 14, 2022

BUY
$2.35 - $4.85 $82,590 - $170,453
35,145 Added 65.87%
88,503 $296,000
Q2 2022

Aug 12, 2022

SELL
$1.96 - $3.04 $132,884 - $206,105
-67,798 Reduced 55.96%
53,358 $141,000
Q1 2022

May 13, 2022

BUY
$2.94 - $9.07 $5,630 - $17,369
1,915 Added 1.61%
121,156 $356,000
Q4 2021

Feb 11, 2022

SELL
$6.07 - $9.68 $8,661 - $13,813
-1,427 Reduced 1.18%
119,241 $1.02 Million
Q3 2021

Nov 12, 2021

BUY
$6.28 - $11.07 $305,201 - $537,990
48,599 Added 67.43%
120,668 $898,000
Q2 2021

Aug 13, 2021

BUY
$7.78 - $15.0 $560,696 - $1.08 Million
72,069 New
72,069 $672,000

Others Institutions Holding RPHM

About Reneo Pharmaceuticals, Inc.


  • Ticker RPHM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,479,600
  • Market Cap $41.1M
  • Description
  • Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as w...
More about RPHM
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.